FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

hours per response:

OMB Number:	3235-0287
Estimated average burd	en

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

affirmative defense 10b5-1(c). See Ins	e conditions of Rule struction 10.							
1. Name and Address Evans Carl A	s of Reporting Person*		2. Issuer Name and Ticker or Trading Symbol CNS Pharmaceuticals, Inc. [CNSP]	Relationship of Reporting Person(s) to Issuer (Check all applicable) Pinches				
(Last) (First) (Middle) C/O CNS PHARMACEUTICALS, INC.		, ,	3. Date of Earliest Transaction (Month/Day/Year) 02/01/2024	- X Director 10% Owner Officer (give title Other (specify below) below)				
	P SOUTH, SUITE 9		4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person				
(Street)				Form filed by More than One Reporting Person				
HOUSTON	TX	77027						
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D)	Beneficial Ownership
			Code	Code V Amount (A) or (D) Price (Instr. 3 and 4)			(Instr. 4)			
Common stock	02/01/2024		P		33,333	A	\$0.3(1)	33,458	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Series A Warrant to purchase common stock	\$0.3	02/01/2024		A		33,333		02/01/2024	02/01/2029	Common Stock	33,333	(1)	78,761	D	
Series B Warrant to purchase common stock	\$0.3	02/01/2024		A		33,333		02/01/2024	10/01/2025	Common Stock	33,333	(1)	112,094	D	

Explanation of Responses:

1. The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.

/s/ Christopher Downs, Attorneyin-fact 02/05/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.